No Data
No Data
No Data
No Data
No Data
BioVie Awarded up to $13.1 Million in Funding From U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the
GlobeNewswire57minutes ago
BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
"Bezisterim" has been approved as the non-proprietary name for NE3107Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammationCAR
BenzingaApr 25 20:29
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated With Alzheimer's Disease and Biomarker Endpoints
Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation
GlobeNewswireApr 25 20:00
BioVie Presents New Data Showing Lead Drug Asset May Promote Healthier Aging | NASDAQ:BIVI
Proactive InvestorsApr 25 17:22
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersImmutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. Syra Health (NASDAQ:SYRA) stock
BenzingaApr 24 20:06
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated With Dementia, Metabolism, and Inflammation
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and
GlobeNewswireApr 18 20:00
No Data
No Data